Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Infectious Mononucleosis 2Epstein-Barr Virus Infections 2Herpes Simplex 1

Interventions

ziprasidone 1Zolpidem 1Warfarin 1Vecuronium Bromide 1Vancomycin 1Valganciclovir 1Tranexamic Acid 1Tobramycin 1Spironolactone 1Sevelamer 1Rocuronium 1Piperacillin, Tazobactam Drug Combination 1Pentobarbital 1Oxycodone 1Nifedipine 1Nafcillin 1Molindone 1Methylprednisolone 1Matrix-M 1Lurasidone Hydrochloride 1Labetalol 1Haloperidol 1Gene-Eden-VIR 1Fosfomycin 1Clozapine 1Ciprofloxacin 1Cidofovir 1Cefepime 1Bosentan 1Aminocaproic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Herpes Simplex × Matrix-M × Clear all
NCT05683834 2026-04-22

Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-seronegative Persons

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
25 enrolled

Herpes Simplex, Infectious Mononucleosis, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡